Journals / Molecular Imaging and Radionuclide Therapy / 2011 / Cilt: 20 - Sayı: 3

Diferansiye tiroid kanserlerinde eski ve yeni TNM sınıflamasına göre mikrokarsinomun değerlendirilmesi

The evaluation of microcarcinoma in differentiated thyroid cancers according to old and new TNM classification

Pages
94–99
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tissue tumor invasion, age, gender and multifocality should also be taken into account. (MIRT 2011;20:94-99)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed to evaluate the tumor size for proximal and distant metastases when the new and old TNM classification is taken into account in differentiated thyroid cancers.
📊
Key Findings & Data:Material and Methods: Two hundred sixty eight patients diagnosed with thyroid carcinoma, undergoing bilateral total or subtotal thyroidectomy treated with high doses of I-131 were examined retrospectively.
💡
Conclusion & Impact:Tissue tumor invasion, age, gender and multifocality should also be taken into account. (MIRT 2011;20:94-99)
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed to evaluate the tumor size for proximal and distant metastases when the new and old TNM classification is taken into account in differentiated thyroid cancers. Material and Methods: Two hundred sixty eight patients diagnosed with thyroid carcinoma, undergoing bilateral total or subtotal thyroidectomy treated with high doses of I-131 were examined retrospectively. The data of these patients were compared after classification, according to tumor size &#8804;1 cm and &#8804;2 cm, lymph node metastases thyroid and tumor capsule invasion at the time of diagnosis, and accumulation of abnormal activity in post I-131 treatment whole-body scan. I-131 uptakes besides physiological and thyroid bed were considered as abnormal activity uptakes. Results: A total of 268 patients with average age of 19-82 yrs (mean: 47.0±13.8 yrs) were included in the study. At postoperative histopathological evaluation, 228 (85.1%) of patients were reported as papillary, 13 (4.9%) as follicular, 23 (8.6%) as well differentiated tumor of unknown malignant potential, 2 (0.7%) as insular and 2 (0.7%) as Hürthle-cell carcinoma. In patients with known tumor size, 96 of 207 (46.4%) patients&#8217; tumor size was &#8804;1 cm and in 111 (53.6%) >1 cm. In the same group, according to the revised TNM classification, in 149 of 207 patients (72%) the tumor size was &#8804;2 cm, whereas in 58 (28%) >2 cm. Of 187 patients with negative lymph nodes, 15 (8%) showed abnormal activity accumulation in the first post I-131 treatment whole-body scan and 10 (40% of 25 patients) positive lymph node (p<0.05) involvement. Conclusion: Since the treatment of patients with microcarcinoma is controversial, tumor size should not be the only factor considered in patients with differentiated thyroid cancer. Tissue tumor invasion, age, gender and multifocality should also be taken into account. (MIRT 2011;20:94-99)

Özet

Amaç: Bu çalışma ile diferansiye tiroid kanserlerinde eski ve yeni TNM sınıflaması dikkate alındığında, tümör boyutunun yakın ve uzak metastaz açısından değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Bu çalışmada tiroid karsinomu tanısı almış, bilateral total veya subtotal tiroidektomi yapılmış ve yüksek doz I-131 ile tedavi almış olan 268 hastanın verileri retrospektif olarak incelenmiştir. Tanı anında lenf nodu metastazı, tiroid ve tümör kapsül invazyonu olan ve cerrahi tedavisinin ardından yüksek doz I-131 tedavisi verildikten sonra tedavi sonrası I-131 tüm vücut tarama sintigrafisinde anormal aktivite akümülasyonu gösteren hastalarda tümör boyutunun ≤1 cm ve ≤2 cm olmasına göre sınıflama yapıldığında elde edilen veriler karşılaştırılmıştır. I-131’in fizyolojik ve tiroid yatağı dışındaki tutulumları anormal aktivite tutulumu olarak kabul edilmiştir. Bulgular: Bu çalışmaya yaşları 19-82 arasında (ort: 47.0±13.8) olan toplam 268 hasta dahil edilmiştir. Postoperatif patolojik değerlendirmede hastalarımızdan 228’i (%85.1) papiller, 13’ü (%4.9) foliküler, 23’ü (%8.6) malign potansiyeli bilinmeyen iyi diferansiye, 2’si (%0.7) insüler ve 2’si (%0.7) Hürthle hücreli karsinom olarak rapor edilmiştir. Tümör boyutu bilinen 207 hastanın 96’sında (%46.4) tümör boyutu ≤1 cm, 111’inde (%53.6) >1 cm idi. Aynı grupta revize TNM sınıflamasına göre tümör boyutu ≤2 cm hastalar dikkate alındığında; 207 hastanın 149’unda (%72) tümör boyutu ≤2cm, 58’inde (%28) ise >2 cm idi. Lenf nodu tutulumu negatif olan 187 hastanın ilk I-131 tedavi sonrası tarama sintigrafisinde patolojik aktivite akümülasyonu olan 15 hasta (% 8) varken, lenf nodu tutulumu pozitif olan 25 hastanın ise 10’unda (% 40) tarama sintigrafisinde patolojik tutulum vardı (p<0.05). Sonuç: Mikrokarsinomalı hastaların tedavisi halen tartışmalı olduğundan, tümör boyutu diferansiye tiroid kanserli hastalarda dikkate alınacak tek faktör olmamalıdır. Tümör invazyonu, yaş, cinsiyet ve multifokalitenin de dikkate alınması gerekir. (MIRT 2011;20:94-99)

🔖

Cite This Article

HASBEK, Z., TURGUT, B., ERSELCAN, T., KOYUNCU, A., BÖRKSÜZ, M. F., TURGUT, N. H., YUMUK, F. (2011). Diferansiye tiroid kanserlerinde eski ve yeni TNM sınıflamasına göre mikrokarsinomun değerlendirilmesi. Molecular Imaging and Radionuclide Therapy, Cilt: 20 - Sayı: 3, 94–99. https://ajindex.com/articles/295202

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sipos JA, Mazzaferri EL. Thyroid Cancer Epidemiology and Prognostic Variables. Clin Oncol (R Coll Radiol) 2010;22:395-404
  2. Besic N, Pilko G, Petrik R, Hocevar M, Zgajnar J. Papillary Thyroid Microcarcinoma: Prognostic Factors and Treatment. J Surg Oncol 2008;97:221-225
  3. Amdur JA, Mazzaferri EL. Incidence, Prevalence, Recurrence, and Mortality of Differentiated Thyroid Cancer. In: Amdur JA, Mazzaferri EL (eds). Essentials of Thyroid Cancer Management. Springer Science+Business Media, Inc. 2005 p:121-41
  4. Martin WH, Sandler MP. Thyroid Imaging. Chapter 30-31. In: Sandler MP, Coleman RE; Patton JA, Wackers FJ, Gottschalk A (eds). Diagnostic Nuclear Medicine. 4th ed. Lippincott Williams&Wilkins; Philadelphia 2003; p:607-670
  5. Robbins LS, Cotran SR, Kumar V. Basic Pathology (Temel Patoloji). Bölüm 20 Endokrin Sistem Hastalıkları; (Çeviri editörü Çevikbaş U
  6. Baskı. Nobel Tıp Kitabevleri Ltd. Şti, İstanbul 2000; s:649-53
  7. Ito Y, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi A. Clinical Outcomes of Patients with Papillary Thyroid Carcinoma after the Detection of Distant Recurrence. World J Surg 2010;34:2333-2337
  8. Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nuc Med Mol Imaging 2009;36:343-346
  9. Lubin E, Mechlis-Frish S, Zatz S, Shimoni A, Segal K, Avraham A, Levy R, Feinmesser. Serum Thyroglobulin and Iodine-131 Whole- Body Scan in the Diagnosis and Assessment of Treatment for Metastatic Differentiated Thyroid Carcinoma. J Nucl Med 1994;35:257-262
  10. Pacini F, Schlumberger M, Dralle H, Elisei R,.Smit JW, Wiersinga W; Europan Thyroid Cancer Taskforce. Europan consensus for the management of patients with differrentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803
  11. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009;19:1167-1214
  12. Van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, Grant CS. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 1992;112:1130-1136. 1